Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Joseph L. Blackshear, Miguel Zabalgoitia, Gregory Pennock, Paul Fenster, Richard Strauss, Jonathan Halperin, Richard Asinger, Lesly A. Pearce

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

Original languageEnglish (US)
Pages (from-to)453-455
Number of pages3
JournalAmerican Journal of Cardiology
Volume83
Issue number3
DOIs
StatePublished - Feb 1 1999

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this

    Blackshear, J. L., Zabalgoitia, M., Pennock, G., Fenster, P., Strauss, R., Halperin, J., Asinger, R., & Pearce, L. A. (1999). Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. American Journal of Cardiology, 83(3), 453-455. https://doi.org/10.1016/S0002-9149(98)00886-8